Score Overview
Explore the 2021 public Archive ranking →
Where Alaunos Therapeutics Inc has ranked, year by year
Showing 10 years ranking history by Net Income Growth.
Has not reached the top 50 on Net Income Growth in any year we have ranked.
- TCRT
2016: 97.5% · 2021: 79.5% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-10-22 | $ 3.04 | — |
1 Year2025-10-22 | $ 2.56 | 18.75% |
5 Years2021-10-22 | $ 237.00 | -98.72% |
10 Years2016-10-21 | $ 832.50 | -99.63% |
20 Years2006-10-20 | $ 847.50 | -99.64% |
All Time2005-08-24 | $ 2.4K | -99.87% |
| Period | Last Price2026-10-22 | 1 Year2025-10-22 | 5 Years2021-10-22 | 10 Years2016-10-21 | 20 Years2006-10-20 | All Time2005-08-24 |
|---|---|---|---|---|---|---|
| Price | $ 3.04 | $ 2.56 | $ 237.00 | $ 832.50 | $ 847.50 | $ 2.4K |
| Return | — | 18.75% | -98.72% | -99.63% | -99.64% | -99.87% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 3K | -$ 4M | $ 124K |
| 2025 | $ 5K | -$ 4M | $ 1M |
| 2024 | $ 10K | -$ 4M | $ 1M |
| 2023 | $ 5K | -$ 35M | $ 6M |
| 2022 | -$ 37M | $ 39M | |
| 2021 | $ 398K | -$ 78M | $ 76M |
| 2020 | $ 0.00 | -$ 78M | $ 115M |
| 2019 | $ 0.00 | -$ 117M | $ 79M |
| 2018 | $ 146K | -$ 53M | $ 61M |
| 2017 | $ 6M | -$ 54M | $ 70M |
| 2016 | $ 6M | -$ 165M | $ 81M |
| 2015 | $ 4M | -$ 120M | $ 140M |
| 2014 | $ 1M | -$ 31M | $ 42M |
| 2013 | $ 800K | -$ 57M | $ 68M |
| 2012 | $ 800K | -$ 96M | $ 73M |
| 2011 | $ 667K | -$ 63M | $ 104M |
| 2010 | -$ 32M | $ 60M | |
| 2009 | -$ 7M | $ 48M | |
| 2008 | -$ 25M | $ 11M | |
| 2007 | -$ 26M | $ 35M | |
| 2006 | -$ 17M | $ 28M | |
| IPO2005 | -$ 9M | $ 8M |
Alaunos Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 0.00 to $ 5K and net income went from -$ 78M to -$ 4M. Revenue increased in 2 of those 5 years; net income in every one.
Between 2015 and 2025, revenue declined from $ 4M to $ 5K and net income went from -$ 120M to -$ 4M. Revenue increased in 3 of those 10 years; net income in 9.
Alaunos Therapeutics Inc currently holds a 5-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.
Membership
Continue TCRT’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 5,119 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
